Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Tuesday: ON Semiconductor Corp (NASDAQ:ONNN), Merck & Co., Inc.(NYSE:MRK), Delta Air Lines, Inc (NYSE:DAL), Bristol-Myers Squibb Co (NYSE:BMY)

• ON Semiconductor Corp (NASDAQ:ONNN), with shares dwindled -50% is now trading at $12.51. The Stock is active as 4.37M shares changed hands versus its average volume of 7.35M shares.

• Merck & Co., Inc.(NYSE:MRK), with shares climbed 77% is now trading at $59.19. The Stock is active as 4.51M shares changed hands versus its average volume of 11.38M shares.

• Delta Air Lines, Inc (NYSE:DAL) with shares declined -0.54% is now trading at $33. The Stock is active as 4.33M shares changed hands versus its average volume of 12.35M shares.

• Bristol-Myers Squibb Co (NYSE:BMY), with shares dropped -1.94% is now trading at $27. The Stock is active as 4.17M shares changed hands versus its average volume of 6.15M shares.

Latest NEWS regarding these Stocks are depicted underneath:

ON Semiconductor Corp. (NASDAQ:ONNN)

On Monday, ON Semiconductor Corp. (ONNN), driving energy efficient innovations, has declared it will change its NASDAQ trading symbol to “ON” – effective upon the market’s open on April 6, 2015. The corporation will continue to operate as ON Semiconductor Corporation.

The move to the new symbol, which is more closely tied with the name of the corporation, is intended to strengthen ON Semiconductor’s brand and is another step towards improving ON Semiconductor’s profile within the investment community.

Starting on April 6, 2015, all corporation information, counting stock trading, filings, and market data related to the corporation, will be stated under the new ticker symbol, “ON.” The CUSIP for corporation’s ordinary stock will remain unchanged. Outstanding stock certificates are not affected by the symbol change and will not need to be exchanged.

ON Semiconductor Corporation manufactures and sells semiconductor components for various electronic devices worldwide. It operates in four segments: Application Products Group, Image Sensor Group, Standard Products Group, and System Solutions Group.

Merck & Co. Inc. (NYSE:MRK)

Today, Merck & Co. Inc. (MRK), declared that the randomized, pivotal Phase 3 study (KEYNOTE-006) investigating KEYTRUDA® (pembrolizumab) contrast to ipilimumab in the first-line treatment of patients with advanced melanoma has met its two primary endpoints of progression-free survival and overall survival. The trial will be stopped early based on the recommendation of the study’s independent Data Monitoring Committee. In KEYNOTE-006, KEYTRUDA demonstrated a statistically noteworthy and clinically meaningful improvement in overall survival and progression-free survival contrast to ipilimumab. The safety profile of KEYTRUDA in this trial was similar to the safety profile formerly stated in advanced melanoma. KEYTRUDA is the first anti-PD-1 therapy to demonstrate a survival advantage contrast to the standard of care for the first-line treatment of advanced melanoma. These data will be presented in the opening plenary session at the American Association of Cancer Research (AACR) Annual Meeting in Philadelphia, April 18-22.

Merck & Co., Inc. provides health care solutions worldwide. The corporation offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.

Delta Air Lines, Inc. (NYSE:DAL)

On Friday, Delta Air Lines, Inc. (DAL), has signed on as a national sponsor for the Congressional Medal of Honor Foundation, furthering its commitment to members of the U.S. armed forces.

As part of Delta’s sponsorship and in recognition of National Medal of Honor Day on March 25, Delta’s support of the Congressional Medal of Honor Foundation centers around sponsorship of educational programming and honoring each of the living 79 Medal of Honor recipients with Diamond Medallion status.

In addition to Diamond Medallion status, the recipients will receive unparalleled benefits ensuring that these heroes and their travel companions experience a smooth and seamless journey each and every time they travel on Delta. All future Medal of Honor recipients will also be awarded this status.

Delta is committed to supporting active military and veterans throughout the U.S. As part of its commitment, Delta partners with the Fisher House Foundation, Luke’s Wings, Marine Toys for Tots, Serving Our Troops, the USO and airport military lounges, counting the Freedom Center in Detroit and the Minnesota Armed Forces Service Center. Whether it’s supporting a new Fisher House facility in Seattle, donating thousands of bikes to the Marine Toys for Tots campaign or serving barbecue at the Bob Hope USO or grilling steaks for the troops with Serving Our Troops, Delta will continue to support the men and women who serve or have served in the U.S. armed forces.

Delta Air Lines, Inc. provides planned air transportation for passengers and cargo worldwide. The corporation operates in two segments, Airline and Refinery. Its route network comprises various gateway airports in Amsterdam, Detroit, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita.

Bristol-Myers Squibb Company (NYSE:BMY)

Today, Bristol-Myers Squibb Company (BMY), declared that it has signed an contract with Novo Nordisk under which Bristol-Myers Squibb will attain an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases. Terms of the contract were not revealed.

The contract supports Bristol-Myers Squibb’s long-standing commitment to immunoscience, a core therapeutic area with multiple innovative drug candidates in development to target immune-mediated diseases with high unmet medical needs.

The innate immune system is the body’s first line of defense against pathogens and responds to exogenous agents in an antigen non-specific way to stimulate an immediate protective response. Dysregulated innate immunity plays a critical role in the induction and pathogenesis of autoimmune diseases.

Bristol-Myers Squibb Corporation discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.